Arbor Biotechnologies sets out CNS gene editing push with three ALS candidates at Meeting on the Mesa
CEO Devyn Smith presented preclinical data from gene editing programs for ALS, with a first CNS IND filing targeted for 2027.
Neurodegeneration
2 stories
Make us preferred on GoogleLatest stories
Page 1 of 1
Clene Nanomedicine's ALS drug is a gold nanocrystal you drink. It missed its primary endpoint. The FDA is still listening.
CEO Rob Etherington and chief scientist Mark Mortenson on the bioenergetic thesis behind CNM-Au8, the HEALEY data, and five meetings with the agency.
